| Olanzapine | hsa00030 | Pentose phosphate pathway | 1.13E-04 | 4 | P60891, P51854, P11413, P37837 | PRPS1, TKTL1, G6PD, TALDO1 | More | |
| Olanzapine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Olanzapine | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
| Olanzapine | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | |
| Olanzapine | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Olanzapine | hsa00520 | Amino sugar and nucleotide sugar metabolism | 1.59E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
| Olanzapine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Olanzapine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Olanzapine | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 7.10E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | |
| Olanzapine | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Olanzapine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Olanzapine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Olanzapine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Olanzapine | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | |
| Olanzapine | hsa01200 | Carbon metabolism | 2.23E-02 | 4 | P51854, P11413, P37837, P60891 | TKTL1, G6PD, TALDO1, PRPS1 | More | |
| Olanzapine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Olanzapine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Olanzapine | hsa03020 | RNA polymerase | 1.81E-02 | 1 | P24928 | POLR2A | More | |
| Olanzapine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Olanzapine | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | |
| Olanzapine | hsa04012 | ErbB signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa04024 | cAMP signaling pathway | 4.80E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.43E-02 | 4 | P09341, P02775, P47992, Q9UBD3 | CXCL1, PPBP, XCL1, XCL2 | More | |
| Olanzapine | hsa04064 | NF-kappa B signaling pathway | 2.99E-02 | 7 | O00463, P14778, Q13077, Q16548, Q8WV28, P24522, P09341 | TRAF5, IL1R1, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | |
| Olanzapine | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
| Olanzapine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Olanzapine | hsa04114 | Oocyte meiosis | 1.35E-02 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Olanzapine | hsa04120 | Ubiquitin mediated proteolysis | 7.08E-04 | 6 | Q14145, Q13042, Q13191, P62837, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, UBE2D2, HERC1, HUWE1 | More | |
| Olanzapine | hsa04145 | Phagosome | 2.94E-02 | 4 | P05164, P78380, P35443, P13765 | MPO, OLR1, THBS4, HLA-DOB | More | |
| Olanzapine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Olanzapine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Olanzapine | hsa04370 | VEGF signaling pathway | 9.69E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Olanzapine | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Olanzapine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Olanzapine | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Olanzapine | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Olanzapine | hsa04625 | C-type lectin receptor signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.97E-05 | 8 | P01375, P20963, Q13153, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, PAK1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Olanzapine | hsa04657 | IL-17 signaling pathway | 3.33E-03 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | |
| Olanzapine | hsa04658 | Th1 and Th2 cell differentiation | 1.99E-02 | 4 | Q04759, P06239, P23771, P13765 | PRKCQ, LCK, GATA3, HLA-DOB | More | |
| Olanzapine | hsa04659 | Th17 cell differentiation | 4.12E-02 | 4 | Q04759, P06239, P13765, P23771 | PRKCQ, LCK, HLA-DOB, GATA3 | More | |
| Olanzapine | hsa04660 | T cell receptor signaling pathway | 3.61E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Olanzapine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Olanzapine | hsa04720 | Long-term potentiation | 4.54E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Olanzapine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Olanzapine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Olanzapine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Olanzapine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Olanzapine | hsa04914 | Progesterone-mediated oocyte maturation | 1.88E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | |
| Olanzapine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Olanzapine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Olanzapine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Olanzapine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Olanzapine | hsa04940 | Type I diabetes mellitus | 6.87E-04 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Olanzapine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Olanzapine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Olanzapine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Olanzapine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Olanzapine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Olanzapine | hsa05032 | Morphine addiction | 1.09E-02 | 2 | P78334, P32298 | GABRE, GRK4 | More | |
| Olanzapine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Olanzapine | hsa05100 | Bacterial invasion of epithelial cells | 4.54E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
| Olanzapine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.10E-03 | 5 | Q16539, Q13153, P09341, P25024, P25025 | MAPK14, PAK1, CXCL1, CXCR1, CXCR2 | More | |
| Olanzapine | hsa05131 | Shigellosis | 2.93E-02 | 6 | Q9NQL2, P0CG47, Q14141, Q96JJ3, Q05397, Q13315 | RRAGD, UBB, SEPT6, ELMO2, PTK2, ATM | More | |
| Olanzapine | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | |
| Olanzapine | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
| Olanzapine | hsa05143 | African trypanosomiasis | 1.51E-03 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Olanzapine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Olanzapine | hsa05146 | Amoebiasis | 3.33E-03 | 9 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB | More | |
| Olanzapine | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Olanzapine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Olanzapine | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | |
| Olanzapine | hsa05170 | Human immunodeficiency virus 1 infection | 3.80E-02 | 5 | Q02750, P62879, P16298, Q05397, Q13315 | MAP2K1, GNB2, PPP3CB, PTK2, ATM | More | |
| Olanzapine | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | |
| Olanzapine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Olanzapine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Olanzapine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Olanzapine | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | |
| Olanzapine | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | |
| Olanzapine | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | |
| Olanzapine | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | |
| Olanzapine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | |
| Olanzapine | hsa05310 | Asthma | 2.27E-02 | 2 | P13765, P12724 | HLA-DOB, RNASE3 | More | |
| Olanzapine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Olanzapine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Olanzapine | hsa05330 | Allograft rejection | 1.51E-03 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Olanzapine | hsa05332 | Graft-versus-host disease | 6.49E-05 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Olanzapine | hsa05415 | Diabetic cardiomyopathy | 4.92E-03 | 5 | Q16718, O14521, Q16539, P49841, P11413 | NDUFA5, SDHD, MAPK14, GSK3B, G6PD | More | |
| Olanzapine | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |
